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A B S T R A C T
Politically authorized reports on personalized and precision medicine stress an urgent need for iner-grained
disease categories and faster taxonomic revision, through integration of genomic and phenotypic data.
Developing a data-driven taxonomy is, however, not as simple as it sounds. It is often assumed that an integrated
data infrastructure is relatively easy to implement in countries that already have highly centralized and digi-
talized health care systems. Our analysis of initiatives associated with the Danish National Genome Center,
recently launched to bring Denmark to the forefront of personalized medicine, tells a diferent story. Through a
“meta-taxonomy” of taxonomic revisions, we discuss what a genomics-based disease taxonomy entails, episte-
mically as well as organizationally. Whereas policy reports promote a vision of seamless data integration and
standardization, we highlight how the envisioned strategy imposes signiicant changes on the organization of
health care systems. Our analysis shows how persistent tensions in medicine between variation and standardi-
zation, and between change and continuity, remain obstacles for the production as well as the evaluation of
genomics-based taxonomies of diference. We identify inherent conlicts between the ideal of dynamic revision
and existing regulatory functions of disease categories in, for example, the organization and management of
health care systems. Moreover, we raise concerns about shifts in the regulatory regime of evidence standards,
where clinical care increasingly becomes a vehicle for biomedical research.
1. Introduction
This paper discusses important limitations and trade-ofs inherent in
contemporary political visions of personalized medicine as a route to
iner-grained and more dynamic disease taxonomies. What is in Europe
mostly called personalized medicine and, in the US, mostly precision
medicine broadly refer to data-intensive strategies that describe and
stratify diseases and patient groups according to an increasing number of
biomolecular factors. The concepts remain “future-oriented” and sui-
ciently lexible to embrace various hopes and expectations for the future
(Brown and Michael, 2003; De Grandis and Halgunset, 2016). As tech-
nologies still in the making, their clinical implications for disease diag-
nostics are inherently di cult to predict. Still, the visions and political
plans are worth analysing because the projection of future goals, whether
realistic or not, drive organizational developments with regulatory im-
plications for science, medicine, and health care (Hogle, 2018).
The concept of regulation carries diferent meanings in diferent
disciplines (Drahos, 2017). Rather than reserving the term for factors
external to the clinical practice, such as legal statutes, we view reg-
ulatory structures as enacted in practice and as constitutive of knowl-
edge production (Cambrosio et al., 2017). We approach regulation in
health care through an analysis of practices that simultaneously enable
and constrain the co-production of biomedical knowledge and disease
categorizations. We emphasize co-production in this context, because
the identiication of genetic biomarkers is dependent on the establish-
ment of new data infrastructures. While policy reports acknowledge the
need for legislative changes to set up such infrastructures, less attention
has been paid to the challenges of using and updating diagnostic codes
that serve other clinical and regulatory functions. Taxonomic revision
depends not only on the availability of genetic data, but also on the
possibility of aligning the new aims with data's existing regulatory
functions.
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Our aim is to show how epistemic and regulatory challenges are
intertwined in attempts to realize a more dynamic and iner-grained
disease taxonomy. We are interested not only in what disease categories
are as epistemic categories, but also in what disease categories do.
Disease categories deine what count as disease and relate symptoms
and test results to treatment plans, but they also increasing serve as
regulatory devices in the management of health care systems and al-
location of social services (Jutel and Nettleton, 2011; Rose, 2013). Di-
agnostic codes are thus performative units that bring together the do-
mains of health, science, administration, and policy (Bossen et al.,
2016). We therefore not only consider disease taxonomies as epistemic
tools for classiication of disease, but also regulatory devices. The reg-
ulatory uses of disease categories may not be as visible as their classi-
icatory role, but the infrastructures installed through these are central
to the operation of health systems (Bowker and Star, 2000; Hoeyer,
2016). Because infrastructures are relational, changes in one domain
impact other parts of the regulatory network. As a result, taxonomic
revision is simultaneously constituted and constrained by the possibi-
lities ofered within a “regulatory web” of mutually dependent relations
(Cambrosio et al., 2017).
By viewing disease categories as performative and regulatory units,
we highlight how they are shaped through negotiations between sci-
entiic, clinical, and political aims. Correspondingly, we not only view
personalized medicine as a scientiic development but also as a political
priority embraced and propagated in strategy reports by political leaders
around the world (NAS, 2011; European Science Foundation, 2012;
Ministry of Social Afairs and Health, 2015; Cyranoski, 2016; Ministry
of Health and Danish Regions, 2016; Genomics England, 2017; National
Institutes of Health, 2018; Australian Genomics Health Alliance, 2019).
The current politics of personalized medicine are characterized by a
strong sense of urgency for acquiring ever more data and for the fast
implementation of new diagnostic categories (Tarkkala et al., 2018).
Although personalized medicine is still a vision for the future, the
ambitions for personalized medicine are already shaping the develop-
ment of new data infrastructures.
The political visions are articulated in large-scale projects such as
the US-based All of Us study (National Institutes of Health, 2018), and
the UK-based 100.000 Genomes Project (Genomics England, 2017).
Making sense of the collected genomic data, however, depends on ac-
cess to infrastructures containing information about current diagnostic
categories. Speciically, it depends on high quality health data on
clinical phenotypes that are suiciently standardized to allow for ana-
lysis via computational tools. The facilitation of this access has resulted
in both American and British e-health initiatives aimed at creating di-
gitally available health data through which each unique case can be
compared to other cases and new patterns can be established (Minari
et al., 2018). Similarly, the European Commission granted another 21
million Euros in 2019 to facilitate digital exchange of health data
within the EU to promote personalized health (European Commission,
2019).
The vision of an integrated health data infrastructure is to a large
extent already established in Denmark, a small European welfare state
with a well-entrenched and centralized system for tracking each in-
dividual patient via unique personal identiication numbers and digital
diagnostic coding systems. To take advantage of this infrastructure,
Denmark has recently embarked on a strategy for personalized medi-
cine to ensure political and legislative facilitation of a national genome
database (Ministry of Social Afairs and Health, 2015). To establish and
operate the infrastructure of the National Genome Center, the Danish
Ministry of Health has recently received approximately 137 million US$
by the Novo Nordisk Foundation (2018), the primary owner of Den-
mark's biggest pharmaceutical company. The aim of the Genome Center
is to store copies of patient's genomes, initially 60,000 people and in
time the whole population, in a manner that facilitates integration and
combination with other types of health data (Danske Regioner, 2015a,
2015b: 11; 34). This is highlighted as important for ensuring that the
data can serve multiple purposes for diagnosis, treatment, and as a
unique data resource for commercial as well as academic research. In
the following, we demonstrate the di culties of aligning these pur-
poses, by illustrating tensions between the epistemic and regulatory
functions of disease codes.
A central aim of recent investments in data infrastructures, as em-
phasized by the Danish Minister for Health, is to “accelerate the process
by which our healthcare system will increasingly treat people based on
knowledge about their genes” (Novo Nordisk Foundation, 2018). To
clarify what a genomics-based diagnostic system entails in practice, we
propose what we call a “meta-taxonomy” of taxonomic revisions. By
opening the “regulatory black box” (Cambrosio et al., 2017) of diag-
nostic infrastructures, we outline a set of important challenges related
to these revisions. We argue that to address these, policymakers need to
understand the epistemic, organizational, and regulatory landscapes in
which knowledge and evidence is produced. This involves acknowl-
edging the challenges of genomic data analysis, and how diagnostic
information, on which this analysis relies, already serves other reg-
ulatory functions. A call for speedy revision works against existing
regulatory uses and risks undermining the quest for safe and trust-
worthy information about likely treatment efects.
2. Methods
This paper began as a theoretical relection on the need for a speedy
and iner-grained revision of disease taxonomies, often articulated in
reports and at conferences on personalized medicine. Rather than an
ethnographic account, we aim to provide an interdisciplinary and
practice-oriented relection on hopes and challenges articulated by ac-
tors in the ield. For this purpose, we combine methods from STS-re-
search and philosophy of science. Together and separately we have
participated in more than 70 conferences, meetings, and workshops in
Denmark and the UK during the period from 2014 to 2018. These
meetings have been documented in extensive ield notes. In addition,
we have analysed reports and other forms of written material de-
scribing precision medicine initiatives and their associated re-
structuring of data infrastructures. Furthermore, Hoeyer has conducted
interviews with administrators, data analysts, and clinicians in the
Danish health services working with health data and data-intensive
medicine in the course of a larger project on data-intensiication in
health care. Submitting qualitative research for ethics committee ap-
proval is not possible in Denmark, but the project complies with the EU
GDPR-requirements. We draw on insights from the exploration of the
Danish data infrastructure to tease out how epistemic and regulatory
challenges are intertwined in the pursuit of personalized medicine.
3. The vision of data integration and speedy taxonomic revisions
Personalized medicine is often promoted as a way to overcome
important limitations within evidence-based medicine (EBM). With
Randomized Clinical Trails seen as the gold standard of evidence, EBM
gives priority to statistical evidence and standardization (Cartwright,
2011; Timmermans and Berg, 2003). Accordingly, diagnostic manuals
such as the International Classiication of Disease (ICD), the Diagnostic
and Statistical Manual of Mental Disorders (DSM), and the International
Classiication of Primary Care (ICPC) prioritize requirements for large-
scale studies of the diagnosis of morbidity, treatment efects, and causes
of mortality (Bowker and Star, 2000). This emphasis places constraints
on the speed of taxonomic revision and the ability to account for special
cases (Solomon, 2011). Although clinicians in practice seek to over-
come the problem of de-individualization (Timmermans and Berg,
2003; Timmermans, 2015), concerns have been raised about the in-
creasing bureaucratic management of EBM and the lack of relevance of
many statistical measures for clinical care (Greenhalgh et al., 2014;
Tonelli and Shirts, 2017).
In response to such limitations, personalized medicine is
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increasingly promoted as a route to a more dynamic disease taxonomy
that can better account for patient variation. Already in 2011, an in-
luential report commissioned by the National Academy of Science
(NAS), entitled “Precision Medicine. A Framework for Developing a
New Taxonomy of Disease”, stressed an “obvious need to categorize
diseases with iner granularity” (NAS, 2011: 29). The report highlights
how the use of multiple molecular-based parameters will lead to a
“more accurate and iner-grained classiication of disease” (46). The
aim is to take advantage of a transformative opportunity provided by the
“explosion of disease-related data with the potential to dramatically
alter disease classiication” (4). Similar visions have been promoted in
many other countries. For instance, the Danish Ministry of Health and
the Danish Regions (which are responsible for the management of the
public health system) maintain that by using genetic knowledge it is
possible to “diagnose diseases more precisely and target treatment more
accurately” (Ministry of Health and Danish Regions, 2016: 3).
Increasing precision in the context of personalized medicine is a
vision of reduced uncertainty of disease diagnostics through molecular
biomarkers that can be “measured accurately and precisely” (NAS,
2011: 42). This is contrasted with the current system, which is de-
scribed as being grounded on an outdated one-size-its-all-approach
that is primarily symptom-based (Ministry of Health and Danish Re-
gions, 2016: 11; NAS, 2011: 10, 42). It is debatable how well this de-
scription captures the current state of the ield. But we shall here focus
on how the ability to update diagnostic categories and tests through
genomic data depends on integration with clinical data on disease de-
velopment, treatments, and health outcomes.
The US NRC report illustrates this task through the development of a
shared infrastructure for clinical practice and biomedical research in a
central igure (Fig. 1), from which the Danish Regions also draw in-
spiration (Jylling, 2017). A centralized database entitled Information
Commons (or Knowledge Commons in the equivalent Danish igure) is
anticipated to give rise to a Knowledge Network that continuously re-
vises and validates new disease categories.
The igure from the NRC report gives the impression that the in-
tegration of genomic data and health data is a fairly straightforward
process of merging existing databases with new types of data, akin to
the development of GIS-type structure underlying Google Maps (NAS,
2011: 17; see also Prainsack, 2015). Yet, data-driven taxonomic revi-
sion via computer analysis presupposes an ability to re-use data across
diferent contexts and for a variety of purposes (Leonelli, 2016). As we
shall see, integrating data – even of the same type and level – often
turns out to be very challenging due to the existence of diverse practices
for diagnosing and coding. We highlight that attempts to overcome
such challenges through regulatory amendments, such as data stan-
dardization, entail signiicant disruptions in health care practices as
well as in standards of evidence. It is not as easy as it may sound.
4. A meta-taxonomy of taxonomic revision
Policy reports on personalized or precision medicine highlight the
urgency of implementation (see also Section 7), but they consistently
lack a speciication of how the new taxonomy is supposed to be de-
veloped. To explore what a iner-grained taxonomy entails in practice,
we outline what we call a “meta-taxonomy” of taxonomy revision. We
illustrate each type of revision with examples from the reports or recent
publications on personalized medicine and discuss the associated im-
plications below. Our aim is to show that the development of new no-
sological categories are intertwined with changes in regulatory prac-
tices (cf. Cambrosio et al., 2017).
The most straightforward interpretation of what more ine-grained
disease categories might entail is what we call stratification into sub-
groups of diseases (Fig. 2A). This type of revision is exempliied through
recently proposed sub-categories of diabetes or cancer through genomic
proiling (Danske Regioner, 2015b: 5, 16). Breast cancer has since the
1970s has been diferentiated into multiple subtypes based on genetic
markers, such as HER2-positive or HER2-negative breast cancers, and
recently further into an increasing number of rare disease variants
(Hedgecoe, 2004; Keating et al., 2016). More generally, research within
cancer genomics, such as The Cancer Genome Atlas, has expanded the
list of cancer subtypes (Tomczak et al., 2015). This type of re-
classiication keeps the overall taxonomic label but distinguishes the
category into more ine-grained disease variants.
The second type, which we call reclassification of previous categories
(Fig. 2B), illustrates how diseases may be redeined in relation to traits
that difer from the previous categorization. This type can result in
merging previously distinct categories according to shared molecular
characteristics. For example, colon and rectal cancers previously were
considered distinct groups but then became grouped together because
of similar patterns of genomic and epigenetic changes (Tomczak et al.,
2015). Alternatively, new disease categories may emerge, as seen in the
recategorization of some organ speciic cancers into biomarker speciic
cancers. In some phase 1 clinical trials, genetic analysis of tumour
biopsies gives rise to the allocation of patients diagnosed with one
Fig. 1. Illustration of the organization of the new taxonomy (NAS, 2011: 2). Reprinted with permission by courtesy of the National Academies Press, Washington,
D.C.
S. Green, et al. 6RFLDO6FLHQFH	0HGLFLQH[[[[[[[[[[²[[[

cancer type to another, (e.g., HER2-related subtypes of breast and colon
cancer, or BRAF and RAS mutations for lung cancer and melanoma).
Recategorizations of this type can thus result in boundary changes in-
volving both lumping and splitting of medical conditions (Featherstone
and Atkinson, 2012: 107)
Type 3 in our meta-taxonomy, clustering of disease and risk groups
(Fig. 2C), represents how diferent diseases may be linked via genetic
markers and lead to clustering of categories based on a network of risk
factors and observed co-morbidities. For example, network analyses of
omics data (genomics, proteomics and metabolomics) have established
links between obesity, diabetes mellitus, and asthma (Barabási et al.,
2011). Similarly, genome-wide association studies have recently iden-
tiied overlaps in genetic markers associated with psychiatric disorders
such as autism, depression, bipolar disorder, and schizophrenia (Gandal
et al., 2018). A central idea is that patients currently belonging to one
disease or risk group are likely also to have or develop other genetically
linked diseases, and that treatment and prevention therefore need to
target several related diseases.
Type 4, expansion of disease categories (Fig. 2D), illustrates how
technological possibilities for detection of iner-grained abnormalities
and pathologies may result in expansion of current disease concepts.
When the deinitions of disease and diagnostic tests are extended to
include phenomena that were previously not part of the diagnosis (e.g.,
genetic markers), the result is often a conceptual expansion of diag-
nostic criteria (Hedgecoe, 2003), as well as an expansion of diagnosed
disease incidence at the population level (Hofmann, 2017). Similarly,
increased focus on early detection and disease prevention has led to the
emergence of risk or predisease categories, which represent a spectrum
between health and disease (Dumit, 2012). Examples are risk categories
of heritable forms of heart disease and pre-diabetes, which have re-
cently been highlighted as actionable targets for disease prevention in
pilot projects of personalized medicine (Price et al., 2017; Perkins et al.,
2018).
Even though it may sound simple and good with a taxonomic re-
vision, our meta-taxonomy shows how a revision can imply many dif-
ferent things and be anything but simple. While our meta-taxonomy
allows an initial appraisal of the diferent types of diagnostic revision, it
is now time to discuss in more depth some of the challenges involved.
We begin with the emphasis on genetic variation and the enduring
uncertainties of genetic information, and then in the subsequent section
explore uncertainties related to phenotypic information that relect the
multiple regulatory functions of disease categories.
5. The focus on genetic variation and the quest of persistent
uncertainty
Our meta-taxonomy illustrates some aspects of what the epide-
miologist Abby Lippman (1992) described as the efects of genetic
technology, namely diferentiation, expansion, and geneticization of
disease concepts. Lippman viewed these developments as driven by a
reduction of biological variation to molecular factors that entails es-
sentialist tendencies. One should be cautious in forecasting the efects
of the application of genetic knowledge in clinical contexts (Arribas-
Ayllon, 2016), especially since implementation often happens in a
piecemeal way where genetic and non-genetic diagnostic practices are
integrated (Hedgecoe, 2002, 2003; Featherstone and Atkinson, 2012).
But since the vision of a iner-grained disease taxonomy foregrounds
genetic variation as a basis for improved disease diagnostics, it is worth
analysing the assumptions underlying the envisioned “genomic en-
lightenment”, as well as the organizational consequences of the pro-
posed strategy (cf. Hedgecoe, 2001).
The borders around the circles in types A and B on Fig. 2 not only
demarcate disease categories but also patient groups that decrease
dramatically in size. Through iner-grained stratiication of diseases and
patient groups, personalized medicine promises to overcome the lim-
itations of classical phase III trials that agencies like the American Food
and Drug Administration (FDA) and the European Medicines Agencies
(EMA) traditionally have seen as the gold standard of evidence.
Whereas classical trials are criticized for being based on population-
based averages, accounting for genetic variation is expected to ofer
higher diagnostic precision. It should not, however, be assumed that
more genetic data will solve the current problems.
We should keep in mind that biomarkers cannot be “read” in the
genome as there is typically no direct or linear causal link to diseases.
Rather, genetic biomarkers are established on the basis of statistical
comparisons of patient groups, or case/control studies, which make the
result prone to potential biases and uncertainties concerning sampling
procedures, size, and variation of the compared data and population
groups. In this context, the interpretation of genetic data thus critically
depends on the deinition of population cohorts with speciic diagnostic
histories and treatment outcomes. But these previous diagnostics are
exactly what personalized medicine is supposed to move beyond or
revise. Taxonomic revision exempliies an attempt to promote reg-
ulatory objectivity (Cambrosio et al., 2017), through systematic co-pro-
duction of new nosological entities and new regulatory norms of action.
It is therefore important not only to identify existing epistemic un-
certainties but also to analyse whether and how policymakers respond
to such challenges.
Despite the grand hopes and expectations expressed in the reports
on personalized medicine, the clinical utility of genetic markers re-
mains a controversial topic and many genetic tests continue to be
marked by great uncertainty (Timmermans et al., 2016; Senn, 2016).
The long-term clinical beneits of targeted cancer therapies are ongoing
issues of debate (Hutchinson and Romero, 2016), and so is the as-
sumption that privileging genetic markers will give more accurate
disease diagnostics (Senn, 2016). The implications of such uncertainties
have been most clearly documented in preventive strategies (C and D
on Fig. 2). At a recent conference in Copenhagen on personalized
medicine, one of the speakers admitted that “we haven't yet developed
good practices for analysing genomic data”. Genomic data are supposed
to give a more precise image of individual patients. However, the
speaker had had his genome sequenced 5 times, and each time the
“genetic mirror” showed a diferent picture of disease risks. The ex-
ample illustrates the common problem that diferent sequencing plat-
forms often give diferent results, and the status of implemented bio-
markers are consistently revised (Timmermans, 2015).
One study found that almost 200 known gene variants previously
seen as predicting risk of disease were found not to be associated with
increased risk anyway (Lek et al., 2016). Similarly, a recently developed
Fig. 2. A meta-taxonomy illustrating diferent ways of ine-graining disease
categories through personalized medicine.
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test for inherited thrombophilia does not change treatment re-
commendations, but nevertheless the US Medicare system received
280,000 claims for the test just in 2014. Despite questionable medical
beneits, this test costs taxpayers approximately half a billion USD a
year (Ross, 2016). Reliance on uncertain genetic tests can result not
only in wasted resources but also in harm to patients. Recently, 21
women underwent prophylactic mastectomies and removal of ovaries
at a Norwegian hospital after testing positive for a variant of the
BRCA2-gene that is no longer considered predictive of disease risk
(Dagens Medicin, 2017). Similarly, a recent case report from the US
documents how two dozen members of the same family were mis-
diagnosed with LQT1 (a hereditary heart disease), because a genetic
test result of uncertain relevance was prioritized over phenotypic evi-
dence indicating normal ECG test results (Ackerman et al., 2016). The
misdiagnosis led to unnecessary implementation of preventive pace-
makers in more than 20 individuals, in one case leading to two shock
incidents in an otherwise healthy individual.
Prioritizing genetic variation is a common feature of many policy
strategies across countries, despite a remarkable lack of convincing
clinical examples to justify this focus (Tarkkala et al., 2018). For in-
stance, a Danish report admits that recent genomics-based studies of
diabetes and ischemic cardiac disease have not resulted in improved
prediction or explanation of these diseases (Danske Regioner, 2015b:
17), but this does not lower the expectations expressed in the same
report of genomics-based disease risk and disease stratiication. Fol-
lowing a more general trend, disappointed expectations do not lead to
relection on whether these are realistic (Brown and Michael, 2003).
Rather, expectations are redeined to be realized at an indeterminate
point in the future – whenever enough data have been collected
(Hoeyer, forthcoming). Thus, the ‘blame’ is shifted onto the quantity of
data currently available, and uncertainties become incentives to collect
ever more data (see also Timmermans et al., 2016). Much the same
happens in scientiic publications when proponents of personalized
medicine are confronted with problems relating to false positive tests
and overdiagnosis (Hood et al., 2015). This should give further reason
for concern about shifts in evidence standards (discussed in Section 6
below).
Why, then, do proponents move so quickly from a description of the
problem of ineicient treatments and poor preventive strategies to
claims that integration of (gen)omics data will improve the situation? In
our view, we cannot see this as an epistemic question alone; it is as
much an economic and political issue. Scientists are under pressure to
align their aspirations with political interests to raise funding, and
governmental agencies need to present themselves as accountable to
public health, which implies opting for immediate health beneits. In an
interview, a person working at the state-level with development of
personalized medicine explained the focus on genetics as a matter of
public accountability: genetics is identiied by the appropriate experts,
she said, as the only area where it is possible to use the data gathered
from the public right away. The state cannot provide funding into pure
research databases documenting metabolism, physical activity, diet,
compliance, or social and psychological factors when such data types
have not been standardized enough to be clinically useful, she argued.
This is the case even though these data might be relevant from a bio-
medical perspective (James, 2014; Smolen and Aletaha, 2013). The
current investments in genetics might not (yet) deliver epistemologi-
cally speaking, but they do respond to a political need.
In consequence, the proposed solution seems to amount to what
Senn (2016) calls a phenotypic squeeze. By this, Senn refers to the trend
to account for complex sources of variation by a reductive fore-
grounding of genetic factors. At the same time, most scientists and even
proponents of personalized medicine acknowledge the di culty of ac-
counting for biomedical complexity through genomics. Speakers at
conferences on personalized medicine often articulate endless socio-
biological variation and continuous interaction between multiple fac-
tors that in efect make each individual unique. Nevertheless, when
moving to concrete suggestions to be implemented, the same people
typically narrowed their focus to disease prediction through analysis of
genomic variation (Ackerman et al., 2016). Personalized medicine in-
itiatives thus opt for the data that are assumed to be most conveniently
collected and standardized. However, in reality, the convenience of
genomic data is hampered by organizational requirements, and by the
complexity of interpretation. An interesting insight from conferences
we have attended is that people often intervene in arguments by saying:
“But we don't know the phenotype!” As argued above, the phenotype is
needed to identify the signiicance of the genotype. For instance,
Genome-Wide Association Studies identify genetic variants on the basis
of a statistical comparison of genomic data from a patient population,
compared to a control group. But, in the absence of reliable phenotypes,
i.e., diagnostic categories to classify population data, the existing di-
agnostic uncertainty is inherited by the genetic algorithm (Lemoine,
2017). This underscores how the interpretation of genomic data is in-
herently dependent on existing systems of classiication, and thus how
genomic data does not ofer an Archimedian point for disease diag-
nostics.
In the following, we highlight how practical problems of integrating
and standardizing phenotypic data reveal inherent structural trade-ofs
between diferent functions of disease codes. The call for speedy revi-
sions of taxonomic systems conlicts with existing regulatory functions
of disease codes and may work against the very ability to make valid
interpretations of phenotypic information.
6. Organizational challenges for data integration
To clarify the organizational challenges associated with speedy
taxonomic revision, we examine the Danish context where minimal
challenges should be expected. Denmark has a long tradition of re-
gistering health data and other information on all citizens in connection
to a personal identiier, the so-called CPR-number derived from the
Central Person Register (Bauer, 2014; Hoeyer, 2018). Denmark should
therefore be an ideal context to realize data integration, and achieving
personalized medicine is considered primarily as a matter of “realizing
the potential by linking what we already know about the population's
diseases with genetic knowledge” (Ministry of Health and Danish Re-
gions, 2016: 3). Again, this may sound easy, but it is not.
Five biorepositories including the Danish Blood Donor Biobank have
undergone integration in 2016 and are administered by the newly es-
tablished Bio- and Genome Bank Denmark. Moreover, new and more
standardized software platforms are being implemented in Danish
hospitals and general practice. Currently, the National Board of Health
Data works to implement a Health Data Programme aimed at enhancing
national integration of phenotypic data while the new National Genome
Centre works to collect, store, and establish standards for genotypic
data. The digital infrastructures through which the data are to be
gathered are not always easy to integrate. For example, two of the ive
regions have recently implemented a new system bought from the US
irm EPIC, and this system faces severe integration problems with the
national databases and registers (Wadman and Hoeyer, 2018).
At various conferences, we have observed how the Danish health
data infrastructure is framed as a unique and available raw material: a
form of ‘oil’ that just needs digital tools to be released. However, even
in this relatively homogenous and highly digitized health care system,
there is considerable variation in local clinical practices for collection,
use, and coding of data. Data might be there, but they are not easy to
ind and require speciic skills to analyse. To illustrate, we provide a
telling example from one of Hoeyer's interviews. Even something as
simple as lab results for a cholesterol measurement have been reported
with diferent digits, or as a yes/no to being above a speciic clinical
guideline level. Just as the reporting format has diferences within and
between laboratories, guideline levels have changed over time. Also,
the facilities performing the measurements change over time when
municipalities, general practitioners or other healthcare providers take
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on or give up on particular functions. As a result, a patient may have
had the same cholesterol level measured continuously for 15 years, but
be reported irst as healthy, later as ill, and then with measurements of
diferent digits. Moreover, data records may be discontinuous or broken
if measurements or information from particular periods are missing. To
know what the data mean over time takes not just a lot of data cleaning
but also quite ine-grained organizational and historical knowledge.
The former president of the International Epidemiological
Association, Rodolfo Saracci (2018) recently commented on the efec-
tiveness of so-called “real world evidence” for realizing precision
medicine. He emphasizes that population-based health registers are the
best sources for this purpose and highlights Danish registers as an ex-
emplary case. But he then stresses that even in this context, the records
do not always provide the information necessary for realizing precision
medicine. He mentions a discussion on a recent Danish cohort study
that claims to document treatment advantages of beta-blockers against
atrial ibrillation in patients with and without heart failure. The study is
impressive in terms of a high population recruitment (200,000 patients)
as well as standardized procedures for reporting of morbidity, co-
morbidity, treatments, etc. However, because the data registers lack
standardized information on ejection fraction (heart pumping capa-
city), the patients could not be stratiied according to the severity of
hemodynamic dysfunction. As a result, concerns were raised about in-
suicient control for confounding efects resulting from within-group
diferences. Saracci uses the examples to highlight that the “real world
studies have ‘local value’ and are indispensable to measure treatment
efectiveness within speciic local (in time and place) circumstances”,
but such diferences also make “inherently uncertain any generalization
of results” (Saracci, 2018: 5).
As has been experienced in multiple research contexts, strategies to
strengthen data-reuse can compromise local uses through a loss of
system-speciic knowledge (Leonelli, 2016). Complex and non-stan-
dardized information is di cult to mine via algorithms, but is often
central to delivering primary health care services to individual patients.
Standardization procedures also raise questions about who is accoun-
table for decisions concerning which classiicatory systems or codes to
adopt when there are discrepancies in existing datasets. The Danish
health care system currently relies on both ICPC coding and ICD-10,
and Electronic Medical Records may contain as many as 140,000 codes
that can be taken from drop-down menus. Although such systems
provide shared languages for data analysis, they easily become in-
tractable in practice.
Through interviews we have learned that one important challenge
for the creation of large-scale searchable databases with structured
patient data is that time pressure and clinical variation tends to make
clinicians opt for broader diagnostics codes, higher in the taxonomy,
and then write the speciics in free-text. It makes the treatment of the
particular patient easier, but the subsequent (re)use of the data more
di cult. Often doctors record breast cancer patients as “DC509, un-
speciied breast cancer”, partly because it is quicker and partly because
DC500-DC508 provide speciications that are not fully adequate for the
patient at hand. Even when speciic codes are chosen, the codes can be
di cult to interpret in isolation from the historical continuity and so-
cial embedding of local practices of data use and data production.
Another key challenge is that the revision of disease taxonomies is
constrained by the embedding of disease categories in various addi-
tional infrastructures. Taxonomic systems play increasing regulatory
roles for record keeping, institutional remuneration schemes, inancial
administration, performance management, quality assurance, as well as
legal functions related to liability issues (Hoeyer, 2016, 2018). New
standardized and iner-grained diagnostic codes cannot be assumed to
be practically applicable in all these systems. In Denmark and many
other countries, disease categories are for instance related to regulatory
categories called Diagnose-Related Groups (DRG) that are central to the
administration of the inances of the hospitals (Bossen et al., 2016).
There are currently 740 DRG-groups with associated tens of thousands
of codes for diagnoses and treatment to categorize patient care. When a
patient is diagnosed and treated, such codes are used to calculate
payments to the hospitals for health and treatment services. For reasons
unrelated to personalized medicine these remuneration systems are also
subject to reforms. Rapid changes in diagnostic codes will therefore
interact with other regulatory changes and cause disruptions in coding
infrastructures that are central to the operation of health systems.
The practical challenges highlight that disease categories are per-
formative and multi-relational units that are embedded in complex
infrastructures, or “regulatory webs”. An important concern is therefore
which efects altered disease codes will have on the various practices in
health care systems. A tension between clinical practice and research
seems to be acknowledged in the US NAS report in a passage stressing
that the taxonomy should “be highly dynamic, at least when used as a
research tool, continuously incorporating newly emerging disease in-
formation” (NAS, 2011: 4, our emphasis). However, this statement
seems at odds with the main aim of developing a joint infrastructure
that simultaneously will be used by research and clinical practice, and
no suggestions are ofered for how to deal with this tension.
7. The need for speed and the remaking of evidence
So far, we have documented how reclassiication of disease cate-
gories based on biomarkers is epistemically and organizationally de-
pendent on the possibility of aligning multiple uses of disease cate-
gories. This can be considered as a “challenge of creating equivalences
between diferent domains of activity, such as laboratory and clinical
activities” (Cambrosio et al., 2017: 165). Cambrosio and colleagues
highlight that regulatory challenges also extend to evidence practices
such as clinical trials. Below, we add to this analysis by highlighting the
regulatory challenges associated with using data from clinical practice
to facilitate research and taxonomic revisions.
The data infrastructure depicted in Fig. 1 relects an attempt to
address the problem that the timeframe for clinical intervention studies
is much longer than genomic innovation (Danske Regioner, 2015b: 23).
The iterative loop of taxonomic revision is framed as a process of “co-
production of health and evidence” (Jylling, 2017). While data in-
tegration and “real time” production of evidence may sound like a
convenient regulatory ix to the slowness of current clinical trials, it
involves a quite signiicant change in the organization of health care.
Progress is here seen as dependent upon developing a “rapid-learning
health care system” that is characterised by a more dynamic relation-
ship between evidence and treatment (Friedman et al., 2010). This
dynamism does, however, come with signiicant practical and ethical
risks (Minari et al., 2018). At the Danish conferences we have attended,
one of the most frequently recurring questions revolves around how to
discover new categories of disease in the course of applying them in
treatment. This amounts to a shift in the regulatory regime of evidence
standards, where evidence is supposed to result from new treatments
rather than being the basis for them.
The vision of faster translation and implementation runs counter to
the evidence hierarchy of EBM that prioritizes statistical evidence as a
precondition for treatment recommendations. While EBM has its critics
(Cartwright, 2011; Solomon, 2011; Greenhalgh et al., 2014; Stegenga,
2018), not least because it fails to take proper account of clinical jud-
gement and experience (Tonelli and Shirts, 2017; Rees, 2000), we
cannot see how personalized medicine presents a feasible alternative at
this stage (see also Lambert, 2006). Admittedly, the use of treatment
outcomes as evidence is not new to medicine, being well documented in
the history of medicine: see for example, Le Fanu's, (1999/2011)ac-
count of the emergence of clinical medicine between the two world
wars (1999/2011). On a more statistically signiicant scale, Danish (and
other) registers that follow patients over time have been an important
source of knowledge about side-efects and other unwarranted aspects
of treatment. However, the evidence that emerges from treatment
usually has a tentative status; for example, post-hoc subgroup analyses
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are usually considered as exploratory only as these are amenable to
biases associated with p-hacking and data ishing (Germain and Baetu,
2017). It is not in itself surprising or even unreasonable that treatments
give rise to evidence. But it is worrying that the reversal of the re-
lationship between evidence and treatment is built into the taxonomic
reconfiguration of disease and treatment guidelines, to be adopted on a
regulatory level, without a clear rationale or justiication.
Despite the uncertainties outlined, the political ambition is never-
theless to realize the potential of personalized medicine in Denmark by
moving fast (Danske Regioner, 2015a, 2015b). The webpage on per-
sonalized medicine by the Danish Regions stresses that “we should not
linger on the debate - we have to act for the beneit of the patients.
Other countries are already well underway, and Denmark must parti-
cipate in the race to take advantage of the opportunities” (webpage of
Danske Regioner, our translation, see also Tupasela, 2017, for an ana-
lysis of national branding in Finland). Similarly, a central message at a
recent conference on personalized medicine was that we do not have
time for further professional or public debate, and that “the talking days
are over!”
The ambition to dissolve existing regulatory thresholds of evidence
without having a viable replacement is particularly disconcerting con-
sidering how Danish reports very explicitly highlight that the new data
infrastructure will open new possibilities for data economies and
public-private partnerships (DAMVAD Analytics, 2016). Similarly, in
the context of initiatives for personalized medicine in Finland,
Tarkkala, Helén, and Snell (2018) observe how expectations have
shifted from a focus on health and targeted treatments to a focus on
‘wealth’, i.e., on potentials for economic growth (Vezyridis and
Timmons, 2017). Meanwhile, evidence for mutual beneits for wealth
and health is in both contexts projected into the future, while existing
doubts are ignored (Hoeyer, forthcoming). This raises important ques-
tions about who will beneit from the new strategies, and about who
will pay if the expectations are not realized.
We do not deny that iterative improvement of diagnostic categories
must be done in an anti-foundational manner – nor do we see this
challenge as speciic to personalized medicine. The philosopher Otto
Neurath used the analogy of boat repair at sea to describe a similar
challenge in economics and science (Stanovich, 2004). What we ques-
tion is thus not the idea of iterative corrections within existing systems
of belief. We have raised concerns about the combination of the epis-
temic and organizational challenges outlined with an accelerated speed
of revision and implementation. Neurath's bootstrapping analogy may be
taken to extremes in personalized medicine. A speaker at one of the
international conferences in Denmark even compared the current de-
velopment of personalized medicine to the thrilling challenge of con-
structing airplanes while lying. The analogies illustrate how iterative
corrections must be made without causing structural disruptions that
would make the boat sink or the plane crash. Similarly, attention should
be taken to revise disease taxonomies in a way that does not risk un-
dermining health care.
8. Conclusion
The promotion of a need for a more dynamic and iner-grained
disease taxonomy exempliies how epistemic, organizational, reg-
ulatory, and political issues intersect when personalized medicine is to
materialize in practice. We have focused speciically on how policy
reports call for a dynamic taxonomy that more rapidly can accom-
modate insights from data-intensive research. Personalized medicine
promotes the epistemic ideal of diagnostic accuracy through a more
precise stratiication of disease categories. In practice, it does so pri-
marily through emphasis on genetic variation, typically without further
justiication of why genetic variation is considered causally privileged
(see also Hedgecoe, 2001).
We have suggested that taxonomic revision is not just a straight-
forward matter of using genetic data to create “more ine-grained
taxonomies”. Since taxonomic revisions can take several forms, each
with diferent epistemic and organizational challenges, we have pro-
posed a meta-taxonomy of taxonomic revisions as a basis for discussions
of evidence thresholds and implications for health care systems. Here,
we have suggested a irst attempt with four types, but just like disease
taxonomies, it will have to develop along with new experiences and
data. A necessary requirement for all types of ine-graining via geno-
mics is, however, that genetic data can be evaluated on the basis of
existing information in terms of reliable, standardized, and continuous
phenotypic data.
Developing an integrated database for research and healthcare is
often pictured as relatively straightforward. However, disease cate-
gories are embedded within larger organizational and regulatory in-
frastructures that simultaneously constitute and constrain the possibi-
lities for diagnostic innovation. By examining the variety of epistemic
and regulatory roles of disease codes, we have pointed to inherent
trade-ofs in the strategies proposed. The ambition of personalized
medicine to ensure a dynamic revision of disease taxonomies is at odds
with requirements for continuity of data, to ensure the preservation and
support of existing health system but also to generate the data sources
personalized medicine needs. Personalization is dependent on the
ability to identify similar patients, which presupposes continuity in the
(historical) health records and across sites. Yet, the aim of a highly
dynamic taxonomy risks undermining existing practices of data gen-
eration and validation, and thereby the very data that personalized
diagnostics need.
Moreover, drawing on the Danish case, we have shown how the
proposed strategy risks disrupting the current regulatory structure of
health care in ways that have previously not received much attention.
Information must be gathered from systems also used as regulatory
devices for various purposes such as institutional remuneration, quality
assurance, inancial administration, data integration, as well as legal
functions related to liability issues. To serve these and clinical purposes
well, and to gather information about local coding practices needed to
assess validity, stable rather than rapidly shifting taxonomies are
needed. We view the competing demands as trade-ofs that must be
carefully balanced, as personalized medicine has not found a way to
overcome persistent tensions between the quest for fast revision and
requirements for continuity in codes and datasets, and between varia-
tion and standardization.
The regulatory challenge is threefold. How can knowledge and
evidence be generated when the status of diagnostic markers, causal
understandings of disease, and principles of categorization and treat-
ment allocation are all under revision at the same time? How will a
highly dynamic revision be possible when diagnostic codes are subject
to multiple regulatory pressures - as tools for performance measure-
ment, as well as epistemic tools for clinical research and practice? How
does the call for taxonomic revision afect standards of evidence?
Legitimate changes in health care regulation need to attend to in-
stitutionalized thresholds of evidence. In the case of personalized
medicine, however, one of the key sources of evidence – phenotypic
information – is envisioned to serve seemingly incompatible global and
local, and epistemic and regulatory, roles. We have suggested that the
current inexhaustible demand for data, together with a sense of time
pressure to develop and implement these strategies, aims to change
notions of evidence in tandem with reclassiication of disease cate-
gories.
Political reports outlining the strategies for realizing personalized
medicine do not acknowledge the existence of trade-ofs or necessary
compromises associated with the proposed strategies. Expectations also
appear unafected by disappointing results and remaining uncertainty
concerning the causal status and clinical utility of genetic markers. We
ind it particularly disturbing that the emphasis on fast implementation
means that policymakers side-step well-known uncertainties and chal-
lenges, and praise accelerated implementation of new treatment forms
as a self-evident solution to the current problem in health care systems.
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In this fast-track environment, individual treatment plans do not need
to rest on ‘best available evidence’ in the classical sense: instead, the
individual case constitutes an experiment that might generate evidence.
Accordingly, we have raised concerns about what may be considered a
form of temporal disruption of evidence, where evidence does not pre-
cede, but follows treatment, and is used to construct the categories it
claims to be based on. Despite the justiied criticisms of EBM, it is not
clear that personalised medicine has yet put in place an alternative
system for knowledge and evidence production that could authorita-
tively supersede it.
Without dismissing the potential of personalized medicine to im-
prove the future of medicine and health care, we wish to stress that it
takes time and careful consideration to provide the desired certainty.
Where such certainty is not available, the appropriate attitude is one of
humility (Jasanof, 2007). If developing personalized medicine is akin
to constructing an airplane while lying, it may turn out to be as di -
cult, and as dangerous, as it sounds. Instead of this ‘daredevil’ attitude,
that lends a kind of glamour to personalized medicine, slowing down
and moderating claims for personalization may be a sounder regulatory
route.
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